Compare Eli Lilly And Co (LLY) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vertiv Holdings Co — how do they compare? Eli Lilly And Co trades at $1,177 (market cap $1.04T), while Vertiv Holdings Co trades at $242.85 (market cap $93.83B). The key difference: Eli Lilly And Co is far larger — about 11.1× Vertiv Holdings Co's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vertiv Holdings Co for 39 Days on average.
| LLY | VRT | |
|---|---|---|
Market Cap | $1.04T | $93.83B |
Volume | 3,064,878 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $1.28K | $376.23 |
52-Week Low | $799.57 | $149.83 |
Typical Hold Time | 93 Days | 39 Days |
Enterprise Value | $1.09T | $94.06B |
Dividend Yield | 0.59% | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Vertiv (VRT) trades at $244.75, down 0.71% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $1.52 versus $1.42 expected, and robust profitability with a net income margin of 15.09% and ROE of 43.94%. Revenue growth is projected to increase from $10.23B in 2025 to $11.5B in 2026. Analyst sentiment remains overwhelmingly positive with a 95.24% buy rating and a consensus price target of $364.94, highlighting confidence in VRT's position in the AI data center infrastructure market.
The outlook for VRT is bullish based on strong earnings momentum and AI-driven demand for data center solutions, though high valuation ratios (P/E of 55.14) and a recent legal investigation pose risks. The stock offers significant upside to the consensus target, but investors should monitor competitive pressures and execution on growth forecasts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
